1. Percentage of patients with xerostomia of grade 2 or worse (Time Frame - 12 month-follow up): will be evaluated by the LENT-SOMA (Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA)) side-effect scale: SOM (1)-(4) (higher score represents higher grade xerostomia), A: objective flow measurement (1) 76-95%, (2) 51-75%, (3) 26-50%, (4) 0-25%
Secondary outcome:
1. Percentage of patients with xerostomia of grade 2 or worse (Time Frame - 6- and 24-months follow up): will be evaluated by the LENT-SOMA (Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA)) side-effect scale: SOM (1)-(4) (higher score represents higher grade xerostomia), A: objective flow measurement (1) 76-95%, (2) 51-75%, (3) 26-50%, (4) 0-25%
2. Locoregional control rate as defined from treatment start to histologically confirmed tumor progression, persistence or last follow up (Time Frame - 2-years): as defined from treatment start to histologically confirmed tumor progression, persistence or last follow up
3. Overall survival (Time Frame - 2-years): as defined from treatment start to death from any cause or last follow up
4. Description of Quality of life - scoring 6 months after treatment, assessed according to the general EORTC-quality of life "core" questionnaire QLQ C30 (overall quality of life for cancer patients) (Time Frame - 6 months after treatment): Questionnaire consists of 30 questions with a maximal score of 100. Absolute scores after linear transformation will be reported as descriptive statistics The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
A high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
See also: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf
5. Description of Head-Neck cancer related symptoms 6 months after treatment, assessed according to the specific EORT-head and neck quality of life supplementary questionnaire HN35 (Time Frame - 6 months after treatment): total scoring of an additional 35 questions with a similar approach to that of the core questionnaire will be reported as descriptive statistics
6. Description of Quality of life - scoring 12 months after treatment, assessed according to the general EORTC-quality of life "core" questionnaire QLQ C30 (overall quality of life for cancer patients) (Time Frame - 12 months after treatment): Questionnaire consists of 30 questions with a maximal score of 100. Absolute scores after linear transformation will be reported as descriptive statistics The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
A high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
See also: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf
7. Description of Head-Neck related symptoms 12 months after treatment, assessed according to the specific EORT-head and neck quality of life supplementary questionnaire HN35 (Time Frame - 12 months after treatment): total scoring of an additional 35 questions with a similar approach to that of the core questionnaire will be reported as descriptive statistics
8. Description of Quality of life - scoring 24 months after treatment, assessed according to the general EORTC-quality of life "core" questionnaire QLQ C30 (overall quality of life for cancer patients) (Time Frame - 24 months after treatment): Questionnaire consists of 30 questions with a maximal score of 100. Absolute scores after linear transformation will be reported as descriptive statistics The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
A high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
See also: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf
9. Description of Head-Neck related symptoms 24 months after treatment, assessed according to the specific EORT-head and neck quality of life supplementary questionnaire HN35 (Time Frame - 24 months after treatment): total scoring of an additional 35 questions with a similar approach to that of the core questionnaire will be reported as descriptive statistics
10. Toxicity rates (Time Frame - weekly during radiotherapy and at 3, 6, 9, 12, 15, 18, 21 and 24 months): evaluated by the CTCAE v5-questionnaires
Pre-defined MR-linac based IGRT and plan adaptation protocol: daily MR-imaging/MR guided radiotherapy once weekly offline plan adaptation to a total of 6
salivary flow measurements: baseline, 6 month-, 12 month- and 24 month-follow up salivary flow measurements and LENT-SOMA subjective/objective evaluation of xerostomia
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"MRI - Guided Adaptive RadioTHerapy for Reducing XerostomiA in Head and Neck Cancer (MARTHA-trial)"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!